0001695357 false --12-31 0001695357 2021-05-12 2021-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 12, 2021

 

PROVENTION BIO, INC.

 

Commission File Number: 001-38552

 

Delaware   81-5245912

(State or other jurisdiction

of incorporation)

 

(IRS Employer

Identification No.)

     

55 Broad Street, 2nd Floor

Red Bank, New Jersey

  07701
(Address of principal executive offices)   (Zip Code)

 

(908) 336-0360

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   PRVB   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On May 12, 2021, Provention Bio, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of common stock from 100,000,000 shares to 150,000,000 shares. Subsequent to such approval, the Company filed, on May 13, 2021, with the Delaware Secretary of State a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”), giving effect to the authorized share increase. The foregoing summary of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is attached as Exhibit 3.1 hereto and is incorporated herein by reference.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

As of the record date for the Annual Meeting, March 15, 2021, there were 63,374,738 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 48,955,603 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 77.25% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each proposal.

 

1.Stockholders elected each of Ashleigh Palmer, Jeffrey Bluestone, Avery Catlin, Sean Doherty, Wayne Pisano, Nancy Wysenski and John Jenkins to serve until the next Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.

 

The votes were cast for this matter as follows:

 

Nominees  Votes For   Votes Withheld   Broker Non-Votes 
Ashleigh Palmer   26,237,374    1,573,301    21,144,928 
Jeffrey Bluestone   27,306,657    504,018    21,144,928 
Avery Catlin   27,223,096    587,579    21,144,928 
Sean Doherty   24,131,741    3,678,934    21,144,928 
Wayne Pisano   19,618,630    8,192,045    21,144,928 
Nancy Wysenski   24,109,246    3,701,429    21,144,928 
John Jenkins   27,262,057    548,618    21,144,928 

 

2.Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following vote:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes 
 26,478,364    1,138,224    194,087    21,144,928 

 

3.Stockholders approved, on a non-binding advisory basis, a frequency of 1 year for future non-binding advisory votes to approve the compensation of the Company’s named executive officers, by the following vote:

 

1 Year   2 Years   3 Years   Abstentions   Broker Non-Votes 
 26,952,367    202,912    397,598    257,798    21,144,928 

 

   

 

 

4.Stockholders approved the amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000 shares, by the following vote:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes 
 40,257,589    8,498,309    199,705    0 

 

5.Stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021, by the following vote:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes 
 48,636,341    181,795    137,467    0 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) The following exhibit is furnished with this report:

 

Exhibit No.   Description
     
3.1   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Provention Bio, Inc.
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

   

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Provention Bio, Inc.
     
Date: May 14, 2021 By: /s/ Andrew Drechsler
    Andrew Drechsler
    Chief Financial Officer